An FDA advisory committee will meet June 9 to discuss the breadth of indication for Sanofi and Regeneron Pharmaceuticals Inc.'s lipid-lowering injectable agent Praluent (alirocumab), including whether the PCSK9 inhibitor is appropriate for patients purported to be "statin intolerant."
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?